Research Topics
| C RueggSummaryAffiliation: University of Lausanne Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesisCurzio Ruegg
Centre Pluridisciplinaire d Oncologie, University of Lausanne Medical School, CH 1011 Lausanne, Switzerland
Biochim Biophys Acta 1654:51-67. 2004..In this article, we review the role of integrins and COX-2 in angiogenesis, their cross talk, and discuss implications relevant to their targeting to suppress tumor angiogenesis...- Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?C Ruegg
Centre Pluridisciplinaire d Oncologie, University of Lausanne Medical School, Switzerland
Endothelium 9:151-60. 2002.... - Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesisC Ruegg
Laboratory of the Centre Pluridisciplinaire d Oncologie, University of Lausanne, Medical School, and Swiss Institute for Experimental Cancer Research ISREC, 155 Chemin des Boveresses, 1066 Epalinges, Switzerland
Cell Mol Life Sci 60:1135-57. 2003..In this article we review the role of integrins in endothelial cell function and angiogenesis. In the light of recent advances in the field, we will discuss their relevance as a therapeutic target to suppress tumor angiogenesis... - Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and realityCurzio Ruegg
Centre Pluridisciplinaire d Oncologie, University of Lausanne Medical School, CH 1011 Lausanne, Switzerland
Ann Med 35:476-87. 2003..In this article we will review recent advances in the understanding of the anti-tumor mechanisms of these drugs and discuss their potential application in clinical oncology... - The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trialsCurzio Ruegg
Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Curr Mol Med 3:673-91. 2003..Future anti-angiogenesis trials integrating biological endpoints and surrogate markers or angiogenesis will require close collaboration between clinical investigators and laboratory-based researchers... - Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathwaysM Hasmim
Division of Experimental Oncology, Centre Pluridisciplinaire d Oncologie, Lausanne Cancer Center, Epalinges, Switzerland
J Thromb Haemost 5:166-73. 2007..The endothelial cells signaling events modulated by zoledronate remain largely elusive... - Clinical applications of TNF-alpha in cancerF J Lejeune
Centre Pluridisciplinaire d Oncologie, Centre Hospitalier UniversitaireVaudois CHUV, Rue du Bugnon 46, CH 1011, Lausanne, Switzerland
Curr Opin Immunol 10:573-80. 1998..Dual targeting is involved; TNF-alpha and IFN-gamma induce apoptosis of angiogenic endothelium, while melphalan induces apoptosis of tumour cells... - Recombinant human tumor necrosis factor: an efficient agent for cancer treatmentF J Lejeune
Centre Hospitalier Universitaire Vaudois, Lausanne, Suisse
Bull Cancer 93:E90-100. 2006..TNF was the first agent registered for the treatment of cancer that improves drug penetration in tumours and selectively destroys angiogenic vessels... - Metabolic labeling and protein linearization technology allow the study of proteins secreted by cultured cells in serum-containing mediaM Colzani
Protein Analysis Facility, Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
J Proteome Res 8:4779-88. 2009..Selected reaction monitoring (SRM)-based quantitation of three proteins of interest in the crude samples yielded data in good agreement with the results from concentration-equalized samples... - MFG-E8/lactadherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cellsC Carrascosa
Division of Experimental Oncology, Centre Pluridisciplinaire d Oncologie, Lausanne Cancer Center, University of Lausanne, Epalinges, Switzerland
Oncogene 31:1521-32. 2012..We conclude that MFG-E8-dependent signaling stimulates cell proliferation and the acquisition of mesenchymal properties and contributes to mammary carcinoma development... - Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cellsJ Zaric
Division of Experimental Oncology, Multidisciplinary Oncology Center CePO, University Medical Center CHUV, University of Lausanne UNIL, Lausanne, Switzerland
Oncogene 31:48-59. 2012..Collectively, these results identify MAG1 as a COXIB-induced inhibitor of the Wnt/?-catenin signaling pathway, with tumor-suppressive and anti-metastatic activity in experimental colon cancer... - 68Ga-NODAGA-RGDyK for ?v?3 integrin PET imaging. Preclinical investigation and dosimetryF Buchegger
Department of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland
Nuklearmedizin 50:225-33. 2011..To visualize neovasculature and/or tumour integrin ?v?3 we selected the binding moiety Arg-Gly-Asp-D-Tyr-Lys (RGDyK) coupled to NODAGA for labeling with 68Ga... - The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine productionM D Puente Navazo
Centre Pluridisciplinaire d Oncologie, University of Lausanne Medical School, Lausanne, Switzerland
J Immunol 167:6431-40. 2001..Altogether, these data demonstrate that the TnFnIII A1A2 domain mediate the ability of tenascin-C to inhibit in vitro T cell activation and provide insights into the immunosuppressive activity of tenascin-C in vivo...